FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14 | Pharmafile
Novartis beats Merck KGaA to U.S. finish line with targeted lung cancer drug Tabrecta | Fierce Pharma
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
FDA approved ALK inhibitors with substantial impact in the field of... | Download Scientific Diagram
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Novartis' Powerful MET Inhibitor Tabrecta Has A Strong Therapeutic Effect On METex14 Mutant Non-small Cell Lung Cancer (NSCLC)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 | Novartis
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study - The Lancet Oncology
MET-dependent solid tumours — molecular diagnosis and targeted therapy | Nature Reviews Clinical Oncology
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Has PD-1 MET Its Match in Hepatocellular Carcinoma? - Gastroenterology
MET Inhibitors Active in Advanced NSCLC | MedPage Today
FDA approves Tabrecta for treatment of metastatic NSCLC
Real-world insights into patients with advanced NSCLC and MET alterations - Lung Cancer
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Safety of Tepotinib in Patients with MET Exon 14 Skipping NSCLC and Recommendations for Management - Clinical Lung Cancer
Met Kinase Inhibitor | CAS 658084-23-2 | SCBT - Santa Cruz Biotechnology
Merck's targeted lung cancer drug tepotinib wins early access in UK -
Novartis bags FDA priority review in tight lung cancer race against Merck KGaA | Fierce Pharma
